AU2092597A - Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds - Google Patents

Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Info

Publication number: AU2092597A
Authority: AU; Australia
Prior art keywords: chemotherapeutic compounds; targeted oligonucleotides; antiproliferative combinations; containing raf; raf
Prior art date: 1996-03-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU20925/97A

Inventor

Karl-Heinz Altmann

Doriano Fabbro

Thomas Geiger

Brett Monia

Marcel Muller

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-07

Filing date

1997-02-24

Publication date

1997-09-22

1997-02-24 Application filed by Novartis AG filed Critical Novartis AG

1997-09-22 Publication of AU2092597A publication Critical patent/AU2092597A/en

Status Abandoned legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000001028 anti-proliverative effect Effects 0.000 title 1
230000000973 chemotherapeutic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU20925/97A 1996-03-07 1997-02-24 Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds Abandoned AU2092597A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US61278796A	1996-03-07	1996-03-07
US08612787		1996-03-07
PCT/EP1997/000875 WO1997032604A1 (en)	1996-03-07	1997-02-24	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Publications (1)

Publication Number	Publication Date
AU2092597A true AU2092597A (en)	1997-09-22

Family

ID=24454663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU20925/97A Abandoned AU2092597A (en)	1996-03-07	1997-02-24	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Country Status (3)

Country	Link
AU (1)	AU2092597A (en)
WO (1)	WO1997032604A1 (en)
ZA (1)	ZA971936B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3215597A (en) *	1996-08-30	1998-03-19	Biomeasure Incorporated	Method of inhibiting fibrosis with a somatostatin agonist
EP1243290A3 (en) *	1998-10-19	2004-03-17	Methylgene, Inc.	Modulation of gene expression by combination therapy
DE69920247T2 (en) *	1998-10-19	2005-09-29	Methylgene, Inc., Saint-Laurent	CHANGE OF DNA METHYLTRANSFERASE BY COMBINATION THERAPY
US6953783B1 (en)	1998-10-19	2005-10-11	Methylgene, Inc.	Modulation of gene expression by combination therapy
CA2352326A1 (en) *	1998-12-22	2000-06-29	Warner-Lambert Company	Combination chemotherapy
US20060052319A9 (en) *	2000-04-03	2006-03-09	Sudhir Agrawal	Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
SI1303527T1 (en) *	2000-07-18	2005-04-30	Leo Pharma A/S	Matrix metalloproteinase inhibitors
EP2251343A1 (en)	2003-05-15	2010-11-17	Arqule, Inc.	Imidazothiazoles as p38-kinase-inhibitors
WO2004103301A2 (en) *	2003-05-16	2004-12-02	Hybridon, Inc.	Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US7829560B2 (en)	2004-07-08	2010-11-09	Arqule, Inc.	1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
JP2008517064A (en)	2004-10-19	2008-05-22	アークルインコーポレイテッド	Synthesis of imidazooxazole and imidazothiazole inhibitors of P38 MAP kinase
US20070275029A1 (en) *	2006-05-26	2007-11-29	Ico Therapeutics Inc.	Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders
EP2125895B1 (en)	2007-02-02	2015-04-08	Vegenics Pty Ltd	Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6080294A (en) *	1992-12-31	1994-08-15	Texas Biotechnology Corporation	Antisense molecules directed against genes of the (raf) oncogene family
AU6633694A (en) *	1993-04-09	1994-11-08	Board Of Regents Of The University Of Nebraska, The	Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides

1997
- 1997-02-24 AU AU20925/97A patent/AU2092597A/en not_active Abandoned
- 1997-02-24 WO PCT/EP1997/000875 patent/WO1997032604A1/en active Application Filing
- 1997-03-06 ZA ZA9701936A patent/ZA971936B/en unknown

Also Published As

Publication number	Publication date
WO1997032604A1 (en)	1997-09-12
ZA971936B (en)	1997-09-08

Publication	Publication Date	Title
AU2093597A (en)	1997-09-16	Chemical compounds
ZA9710314B (en)	1998-05-18	Chemical compounds.
AU2440997A (en)	1997-10-29	Calixpyrroles, calixpyridinopyrroles and calixpyridines
AU1492397A (en)	1998-03-26	Desiccant container
ZA975436B (en)	1997-12-22	Chemical Compounds.
ZA975951B (en)	1998-01-06	Chemical compounds.
AU5259498A (en)	1998-05-29	Antisense oligonucleotides
DE69723848D1 (en)	2003-09-04	3-descladinose-2,3-anhydroerythromycin-derivate
AU2092597A (en)	1997-09-22	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
ZA975742B (en)	1997-12-29	Modified oligonucleotides.
AUPP433398A0 (en)	1998-07-16	Compounds and processes
AU1124099A (en)	1999-05-17	Double ended carrier
ZA975079B (en)	1998-01-14	Packet radio systems.
AU7104398A (en)	1998-12-08	Conopeptides auia, auib and auic
AU8682998A (en)	1999-06-07	Improvement in chemical analyses
AU3166897A (en)	1998-01-14	Factor vii-binding reagent
EP0678548A3 (en)	1996-09-04	Antimicrobial materials.
AU8228698A (en)	1999-02-08	Porous container
AU7130998A (en)	1998-11-13	Ethyleneimine-containing resins, manufacture, and use for chemical separations
AU9006998A (en)	1999-03-29	Desiccant
AU5960896A (en)	1997-08-11	Oxidation-reduction process
ZA984689B (en)	1999-12-01	Polymeric materials.
AUPP003297A0 (en)	1997-11-20	4,5-diaryloxazole compounds
AU1018897A (en)	1997-07-24	Envelope printing
AU3961899A (en)	1999-11-23	Chemotherapeutic treatment